Personal information

No personal information available

Activities

Collapse all

Works (3)

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease

Clinical Pharmacokinetics
2025-02-05 | Journal article
DOI: 10.1007/s40262-025-01482-8
Contributors: John A. Hey; Jeremy Y. Yu; Susan Abushakra; Jean F. Schaefer; Aidan Power; Pat Kesslak; Jijo Paul; Martin Tolar
Source: check_circle
Crossref

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model

Drugs
2024-07 | Journal article
DOI: 10.1007/s40265-024-02068-7
Contributors: John A. Hey; Jeremy Y. Yu; Susan Abushakra; Jean F. Schaefer; Aidan Power; Patrick Kesslak; Martin Tolar
Source: check_circle
Crossref

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

Drugs
2024-07 | Journal article
DOI: 10.1007/s40265-024-02067-8
Contributors: John A. Hey; Susan Abushakra; Kaj Blennow; Eric M. Reiman; Jakub Hort; Niels D. Prins; Katerina Sheardova; Patrick Kesslak; Larry Shen; Xinyi Zhu et al.
Source: check_circle
Crossref
How many people are using ORCID?